By Lori Abrams
Those who know me understand the value I put on bringing the voice of the patient and caregiver into the drug development process. They also know that I believe that todays terminology phrases like patient-centricity, patient at the center, and other sexy mottos is sometimes used by organizations to show the world that the patient is at the forefront of everything they do. But are they really? Is patient feedback on a protocol enough to prove that their voices are heard? Is providing input on an informed consent what a patient really wants to do? Maybe.
How often has an organization asked the patient and caregiver how they would like to contribute to a drug development program? If they could do anything to help bring a drug to the market, what would that look like? Moreover, if a trial participant could provide ongoing feedback that improved the patient experience, what would they contribute, and how might the trial change?
Lets try it now. I am humbled to introduce readers to Amy Butler. Together, we are going to try to shed some light on the drug development process from the perspective of a brave woman who has participated in five clinical trials. First, a brief summary of Amys experience
Amy was a medical assistant for a large obstetrics and gynecology practice near her home in McHenry, IL, where she lives with her husband and two children (along with two cats, a quacker parrot, and a corgi puppy). Advocacy has always been a part of her life, as she has a brother who is developmentally disabled. But she never expected that her biggest challenge as an advocate would be to try to save her own life.
In 2014, at 44 years of age, Amy was diagnosed with stage IV colon cancer with metastasis to the liver. At the Mayo Clinic, she had a right hemicolectomy and liver resection, along with a prophylactic hysterectomy because she discovered through genetic testing that she had a CHEK2 variant. She underwent six months of Folfox chemotherapy with Avastin and was deemed cancer-free. Nine months later, a follow-up scan revealed that she had metastatic disease in both lungs. She began Folfiri with Avastin; however, after about 10 months, scans started showing progression in her lungs.
Against her Mayo Clinic oncologists advice, she began looking into clinical trials. Fortunately, her support group Colontown (see related article) provided her with science-based information about clinical trials. Her local oncologist referred her to the University of Chicago. Over the next two years, she participated in four clinical trials. Three of the trials were immunotherapy in combination with other drugs and one was an antibody trial. Due to progression, she returned to her local oncologist and revisited standard chemotherapy for a few months, with no success. Recently, Amy was approved to start her fifth clinical trial.
Amy was kind enough to answer my questions about her journey, providing an unvarnished look at clinical trials from a patients perspective and shedding light on aspects of the clinical trial process in desperate need of improvement.
Lori Abrams: You were at the Mayo Clinic and clinical trial participation was not supported. Can you describe what occurred and why?
Amy Butler: I was at Mayo Clinic for a follow-up visit and my oncologist was going over my latest CT scan results. The scans showed that my cancer was progressing while on Folfiri chemotherapy. Upon hearing this news, I told my oncologist that I thought it was time to look into clinical trials. He didnt agree with me. His recommendation was I should take a break from chemotherapy, as I was completely worn out from treatment. He felt that after a month off I would be strong enough to start treatment again in hopes of keeping my cancer at bay. Knowing that I had a mutation in the KRAS gene, I understood that I had fewer treatment options and this terrified me. I didnt want to settle; I wanted more options. After further discussion, I was told that Mayo Clinic had no clinical trials to offer me and there was no mention of any other facilities that I should consult with.
Abrams: How did it feel when you were not offered alternative options to standard care by your Mayo oncologist? What were your next steps?
Butler: It was terrible; I felt so alone. Here I was at one of the countrys premier medical facilities, and all Im offered was to continue standard of care chemotherapy, even though it clearly wasnt working anymore. My next step was to see my local oncologist and discuss my recent scans with him. This conversation was quite different from my conversation at Mayo Clinic. My local oncologist really listened to my concerns about continuing with the same chemotherapy treatments and when I asked him about clinical trials, he was on board. I walked out of that appointment with a referral to the University of Chicago. Two weeks later, I was signing a consent form for my first clinical trial.
Abrams: How and when did you find Colontown?
Butler: When I was diagnosed with stage IV colon cancer in 2014, I followed all the rules. One of those rules was to stay off the internet. In 2016, when I learned that the cancer had metastasized to my lungs, I threw that rule out the window and began looking for answers. I came across a blog called Adventures in Living Terminally Optimistic by Tom Marsilje. Tom was an oncology researcher who was also diagnosed with colon cancer at a young age. I was inspired by Toms blog; it filled me with hope again. On his blog, Tom mentioned many colon cancer support groups. I was overwhelmed with the amount of support out there. I couldnt believe that my doctors never mentioned or recommended them.
I contacted Tom and we had a great discussion about new treatments coming for colon cancer patients. He talked to me about the different support groups and recommended that I join Colontown.
Abrams: Colontown helped you understand clinical trials. What type of information did they provide? Did they provide navigation to clinical trials? How did they help you to better understand your disease?
Butler: Colontown became my lighthouse in the dark. First, let me explain how Colontown works. When you join Colontown, the administrators invite you to join private patient-lead neighborhoods. Each neighborhood is based on the stage, tumor mutations, and metastatic disease. The clinical trial neighborhoods are broken down into groups based on microsatellite instability (MSI) status as well as mutations.
Through Colontown, I was educated about what my MSI status (mine being microsatellite stable, or MSS) and my KRAS mutation meant. Not only was I able to grasp my disease, I also met wonderful people who were going through the same thing. Within the MSS clinical trial neighborhood there is a link to the Late Stage Trial Finder that was curated by Fight CRC and created by Marsilje, a scientist and Colontown member.
Abrams: You have participated in five clinical trials. Were you asked to provide feedback (good or bad) before, during, or after your participation?
Butler: The answer to this is a resounding no. The only feedback Im asked to provide is what my side effects are during treatment.
Abrams: If you could be an advisor to drug development process at a company, what would that look like?
Butler: I believe that a patient has the right to know the results of any specialized testing that was done. Ive had to have multiple lung biopsies in clinical trials, and I wasnt told why or what they were looking for. Ive had blood draws where 15 tubes of blood were taken, and I have no idea if anything interesting was found. I think patients deserve to get some results. Pharmaceutical companies should issue symptom diaries for the trials because a patient may forget how they were feeling by the time of their next appointment. A patient wants to know how their participation helped in the clinical trial.
Abrams: Were the results of the first four studies shared with you after the study closed? Did any of the sites ever reach out with results?
Butler: No; sadly, Ive never heard any results from the clinical trials Ive participated in. I feel that the facility site should get the results and share it with the patients who participated in them.
Abrams: Would you describe some of the best practices that made you feel safe, valued, and appreciated at a clinical trial site?
Butler: The facilities nurse navigators are amazing. They are your sounding board and liaison between the patient, doctors, and pharmaceutical company. The nurses who administer the treatments are some of the kindest people that I have ever met. In one of the clinical trials I participated in, I was required to stay near the facility for 10 days for daily blood draws. This meant that I couldnt go home because I lived too far away. When I went to the clinic on a Saturday for my blood draw, one of the nurses brought her puppy and they were waiting outside for me. She knew that I was homesick, and her cuddly puppy gave me the boost I needed to get through my stay.
Abrams: Conversely, would you describe experiences that made your participation difficult and or frustrating?
Butler: Overall, the waiting time is the most frustrating part of participating in a clinical trial, especially in the larger clinics. The waiting time between the signed consent and the start date, time spent sitting in waiting rooms for blood draws and CTs, and anxiously waiting for test results.
Abrams: If you could provide feedback to a sponsor (pharmaceutical company) on how to design and execute a better clinical trial for people with cancer, what would you tell them?
Butler: I would ask the pharmaceutical companies to send surveys to the treatment sites for patients to fill out periodically. This would give the patients an opportunity to give their opinions while still remaining unidentified. I would like the sponsors to make it easier for the patients to get results of the clinical trial that they participated in.
Abrams: Have you heard the phrases I mentioned above? Patient-centricity, patient at the center, etc.? What do they mean to you?
Butler: Yes, I am familiar with those terms. For me, patient-centricity means that I have some control in my clinical trial journey. Not only am I being treated, but I am being cared about. Im not just a number.
Abrams: Amy, what do you want people to know about clinical trials and/or participating in clinical trials that we have not discussed?
Butler: I think that clinical trials should be part of the discussion early on in a patients cancer journey. Too many patients are waiting until its too late to start clinical trials because they are made to feel that its taboo to bring it up to their oncologist. I want the pharmaceutical companies to never lose sight that we are people who are desperately trying to beat cancer, or at least be able to live longer with cancer. We cant afford to waste time.
Abrams: This is Amys journey, not mine. Therefore, Amy will provide the ending to this article. I hope you have been touched by Amys words, strength, and courage. Together, we can continue to improve clinical research for the patients. They are our friends, our family members, and ourselves.
Butler: Although my participation in clinical trials has not cured me, I do believe they have extended my life. I was given a 30 percent chance to live five years when I was diagnosed, and here I am almost five years later. My disease has recently taken a dark turn, as I just learned that my fifth clinical trial has failed. My tumors have grown and now I have bone involvement. My treatment options are dwindling, but I refuse to give up because when it gets down to it, I just want to live.
Postscript: On the day of discontinuation of clinical trial No. 5, Amy decided that going back to a standard course of therapy was not going to be her path. She inquired about an NIH clinical trial. The oncologist agreed that this was a good idea. Once again, Amy left a doctors office with a good idea, but without a referral or contact name or number. However, there is good news. The following week, she was screened for a trial at NIH, and eight days later, she was accepted to be a patient participant.
About The Author:
Lori Abrams is senior director of Patient Advocacy, a new division at WCG Clinical. She previously was in R&D at Bristol-Myers Squibb for 20 years, the last five as director of Diversity and Patient Engagement. This group integrated the voice of the patient and caregiver into the clinical trial process, developed relationships in the disease-based and minority-focused communities, and helped colleagues understand the challenges of those living with diseases. You can email her at firstname.lastname@example.org.
- Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Instant... - February 15th, 2020
- Cancer Biological Therapy Market Top Key Players, Size, Global Share, Trend, Segmentation, Demand, Opportunities And Forecasts To 2025 - Chronicle 99 - February 15th, 2020
- Outlook on the Gene Therapy for CNS Disorders Market to 2025 by Application, - News by aeresearch - February 1st, 2020
- Cancer Biological Therapy Market Size, Share, Technology, Included Features, Cost, Revenue, Manufacturers, Region, Applications and Forecast to 2025 -... - January 31st, 2020
- Global Age Related Macular Degeneration (AMD) Market: Industry Analysis and Forecast (2019-2026) - Expedition 99 - January 31st, 2020
- UAB: 50 years of Improving Birmingham, Alabama and the World - Birmingham Times - January 31st, 2020
- Parkinsons Disease Treatment Market 2020 Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Science... - January 31st, 2020
- What can hold back the hands of time? Scientists have looked at these five treatments - Ottawa Citizen - January 31st, 2020
- Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2018-2026) - Bulletin 99 - January 25th, 2020
- MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich's Ataxia - P&T Community - January 14th, 2020
- Oncocyte Announces the Commercial Availability of DetermaRx, the First Test for Chemotherapy Benefit Prediction in Patients with Early Stage Non-Small... - January 14th, 2020
- The Region's Health Leaders on What's New and What the Next Decade Will Bring - Business West - January 9th, 2020
- Endothelial Dysfunction Industry 2019-2025 Market Analysis by Size, Share, Growth, Regional, Manufactures, Application and Forecast Research Report -... - January 9th, 2020
- Cell Harvesting Market is Expected to Reach USD 387.9 Million by 2025| Bertin, Tomtec, Terumo BCT, HynoDent AG, Avita Medical, Argos Technologies -... - January 9th, 2020
- Insights on precision oncology developments in Japan and beyond - MobiHealthNews - January 6th, 2020
- Novel discovery in gene therapy to treat kidney diseases - WeForNews - January 5th, 2020
- Top Providers of the Alpha Thalassemia Market gives a New Dimension easing Measurement and Quantification - GuruFocus.com - December 27th, 2019
- This was the best health news over the last decade - USA TODAY - December 18th, 2019
- US Network of Specialized Angelman Clinics to Double Thanks to New Partnership - Angelman Syndrome News - December 13th, 2019
- ICMR issues guidelines for gene therapy in India - Daily Pioneer - December 13th, 2019
- Mergers and Acquisitions Will Strengthen Payer Identity in 2020 - HealthPayerIntelligence.com - December 13th, 2019
- University of Iowa researchers say $18 million grant could soon lead to cure for rare brain disease - KCRG - December 13th, 2019
- Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Tribunal... - December 13th, 2019
- Cancer gene therapy backed by Blackstone gets trial win - BioPharma Dive - December 6th, 2019
- Counterculture 73: Summer Jam, Timothy Leary and the Sexual Revolution - Rolling Stone - December 6th, 2019
- Precision Cancer Therapies Market Size, Status and Forecast 2025 Trends, Size, Drivers, Strategies, Products and - The Market Stats News - December 6th, 2019
- World AIDS Day 2019: 37.9M people worldwide were living with HIV at the end of 2018 - USA TODAY - December 2nd, 2019
- Global Parkinsons Disease Treatment Market 2019 Analysis by Industry Growth, Size, Share, Trends and Forecast by 2025 - Eastlake Times - November 30th, 2019
- Diabetic foot wounds kill millions, but high-tech solutions and teamwork are making a difference - Thehour.com - November 28th, 2019
- Macular Degeneration Treatment Market and its Future Outlook and Trend During the Period of 2019 2026 - The Chicago Sentinel - November 25th, 2019
- Edited Transcript of BLFS earnings conference call or presentation 12-Nov-19 9:30pm GMT - Yahoo Finance - November 20th, 2019
- U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa - Ottawa Citizen - November 18th, 2019
- Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia... - November 18th, 2019
- Abuse in cell banking services a global problem - Bioprocess Insider - BioProcess Insider - November 14th, 2019
- Anti-Aging Products and Therapies Market Outlook: Investors Still Miss the Big Assessment - The Market Journal - November 11th, 2019
- Tip Sheet: A clever way to make an AIDS vaccine; how a common cancer mutation actually drives cancer; and a new process that regulates red blood cell... - November 9th, 2019
- Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) - The Market Expedition - November 6th, 2019
- Davenport & Company Upped By $3.56 Million Its Sgmo (SGMO) Holding; EMPOWER CLINICS ORDINARY SHARES (EPWCF) Shorts Raised By 2360% - MS Wkly - November 6th, 2019
- Dr Batra's have launched a new genetics-based therapy that predicts future diseases - Gulf Today - October 31st, 2019
- Deepak Chopra Has Never Been Sick - The New Yorker - October 18th, 2019
- Parkinsons Disease Treatment Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2025 - The Ukiah Post - October 11th, 2019
- Transfusion-dependent Anemia Treatment Market Gain Impetus due to the Growing Demand over 2019 2029 - Herald Space - October 1st, 2019
- Non-viral Gene Therapy will now accelerate cancer study - Industry Reporter - September 28th, 2019
- Social Impact Heroes: How Lynn OConnor Vos and the Muscular Dystrophy Association are helping to raise billions of dollars to fund research to... - September 28th, 2019
- Pollard and Norris in the race for Pos. 2 of the Public Hospital District 4 - Snoqualmie Valley Record - September 28th, 2019
- Nearly Half of Poland's SMA Patients on Track to Get Spinraza, Experts Say - SMA News Today - September 28th, 2019
- Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 Mutations - Renal and Urology News - September 28th, 2019
- Precision Cancer Therapies Market Forecast Research Reports Offers Key Insights 2017 2025 - Space Market Research - September 28th, 2019
- Google bans ads for 'bad actors' selling 'deceptive treatments' - BioEdge - September 22nd, 2019
- Texas State To Expand Round Rock Campus Programs, Services - Round Rock, TX Patch - September 22nd, 2019
- Transfusion-dependent Anemia Treatment Market Size, Status and Growth Opportunities by 2025 - The Market Plan - September 22nd, 2019
- Chemotherapy Drugs Market Strategies, Major Industry Participants, Marketing Channels and Forecast To2018 2028 - Commerce Gazette - September 22nd, 2019
- Targeted Cancer Therapies Market Regional Landscape, Production, Sales & Consumption Status and Prospects 2025 - Commerce Gazette - September 22nd, 2019
- Precision Cancer Therapies Market to Witness Comprehensive Growth by 2017 2025 - Technology Trend - September 22nd, 2019
- Biological Product Manufacturing Market Analysis, Size, Regional Outlook, Share, Trend, Growth, Analysis and Forecast - Rapid News Network - September 22nd, 2019
- Google Bans Advertising on Unproven Medical Treatments (like Stem Cells) - Bedford Bulletin - September 22nd, 2019
- 4 Barriers To Cell And Gene Therapy Development For Rare ... - May 18th, 2019
- Gene Therapy: The New Frontier for Inherited Retinal Disease - April 16th, 2019
- Nutrition : The Addiction Recovery Guide - March 25th, 2019
- F.D.A. Speeds Review of Gene Therapies, Vowing to Target ... - February 17th, 2019
- Cell and Gene Therapy Center - IQVIA - December 24th, 2018
- resurrection-clinics.eu - August 24th, 2018
- Hacking Your Genes Has Never Been Easier - Outside Magazine - September 8th, 2017
- FDA approves first cell-based gene therapy for use in the United States - Gears Of Biz - September 8th, 2017
- Quick Hits: Withdrawn Leukemia Drug Returning, Drugmaker in $58M Settlement Over Sales Reps, and More - MedShadow (registration) (blog) - September 8th, 2017
- FDA Approves New Cancer Treatment - Alive For Football - September 5th, 2017
- Global Cancer Biological Therapy Analysis & Forecast 2016 to 2023 - Digital Journal - September 5th, 2017
- How one California county is fighting high-priced surgeries - Los Angeles Times - September 2nd, 2017
- New 'hit-and-run' gene editing tool temporarily rewrites genetics to treat cancer and HIV - GeekWire - September 2nd, 2017
- Australian Market Declines - Markets Insider - August 29th, 2017
- New Stanford drug saves child with deadly genetic disease - The Mercury News - August 25th, 2017
- Orphan Diseases Market Key Players analysis ... - Digital Journal - Digital Journal - August 25th, 2017
- Gene Editing in Human Embryos Leaps ForwardHere's the Science - Singularity Hub - August 22nd, 2017
- Global Cancer Biological Therapy Market 2017 Size, Development Status, Type and Application, Segmentation ... - Digital Journal - August 22nd, 2017
- Traditional Therapy Clinics Ltd (TTC.AX) Money Flow Index Levels in Focus - Stock Daily Review - August 22nd, 2017
- Sodium Iodide Symporter for Nuclear Molecular Imaging and ... - August 13th, 2017
- Biological bypass shows promise in coronary artery disease - Medical Xpress - August 12th, 2017
- Cardiovascular disease cure? One session of THIS could help treat condition - Express.co.uk - August 9th, 2017
- Understanding the muscle behind global duchenne muscular dystrophy market - WhaTech - August 9th, 2017
- Proton Therapy: How It Could Change The Outcome of Paediatric Cancer - HuffPost - August 5th, 2017